Leidos receives DTRA contract to research WMD countermeasures
The multiple award, indefinite delivery/indefinite quantity contract includes a five-year base period of performance, a five-year option and a total value of approximately $4 billion for all seven awardees if all the options are exercised. Leidos received the contract under the Combating Weapons of Mass Destruction Research and Technology Development ID/IQ contract.
PositiveID entered into a teaming agreement with Leidos in October 2012. The agreement connected Leidos' system engineering and integration capabilities with PositiveID's biothreat detection technologies. PositiveID will offer its microfluidics-based bioagent networked detector (M-BAND) airborne biothreat detector and its Firefly Dx handheld diagnostic system as part of the teaming agreement.
"We are very pleased that our teaming partner, Leidos, has been awarded this significant ID/IQ contract, and we look forward to demonstrating the ability of our Firefly and M-BAND technologies to combat weapons of mass destruction," William Caragol, the chairman and CEO of PositiveID, said.
PositiveID's M-BAND continuously and autonomously analyzes air samples to detect biological airborne threats in the form of toxins, viruses and bacteria. Firefly Dx is a point-of-need, handheld system meant to deliver molecular diagnostic results in real-time.